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0014-5793  2012 Federation of European BiochemicProtein disulﬁde isomerases (PDIs) are a family of foldases and chaperones primarily located at the
endoplasmic reticulum that catalyze the formation and isomerization of disulﬁde bonds thereby
facilitating protein folding. PDIs also perform important physiological functions in protein quality
control, cell death, and cell signaling. Protein misfolding is involved in the etiology of the most com-
mon neurodegenerative diseases, including Alzheimer, Parkinson, amyotrophic lateral sclerosis,
Prion-related disorders, among others. Accumulating evidence indicate altered expression of PDIs
as a prominent and common feature of these neurodegenerative conditions. Here we overviewmost
recent advances in our understanding of the possible functional contribution of PDIs to neurode-
generation, depicting a complex and poorly understood scenario. Possible therapeutic beneﬁts of
targeting PDIs in a disease context and their use as biomarkers are discussed.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Protein disulﬁde isomerases (PDIs) are emerging as important
factors in health and disease in recent years (reviewed in [1]). Spe-
cial attention has been given to the contribution of PDIs to the
pathogenesis of many neurodegenerative disorders including Alz-
heimer’s disease (AD), Parkinson’s disease (PD), Huntington’s dis-
ease (HD), prion related disorders (PrDs) and amyotrophic lateral
sclerosis (ALS). The accumulation of abnormal protein inclusions
is a hallmark of all these pathologies [2], which are collectively
classiﬁed as protein misfolding disorders (PMDs) [2]. These dis-
eases are generally related with aging and a progressive decline
and failure of cellular protein folding and quality control systems
[3,4]. Speciﬁc mutations in an underlying gene (familial cases) or
structural changes of a normal protein (sporadic cases) are the
cause of the accumulation of misfolded proteins in PMDs, which
are present in the form of small oligomers, aggregates or large
inclusions or extracellular deposits [5]. Although the mechanisms
involved in the pathogenicity of most PMDs are not fully under-culty of Medicine, Institute of
ile, Santiago, Chile.
.harvard.edu (C. Hetz).
al Societies. Published by Elsevierstood, disturbance of basic neuronal processes are consistently re-
ported as a potential cause of neurodegeneration, highlighting
alterations in axonal transport, synapse formation and mainte-
nance, redox balance, proteasome function, mitochondrial function
and protein homeostasis [6].
2. ER stress in neurodegeneration
Chronic protein folding stress at the endoplasmic reticulum
(ER) is linked to a number of neurodegenerative diseases [7]. In
fact, many speciﬁc defects are observed in the secretory pathway
in PMDs, and involve physical interactions of disease-related pro-
teins with components of the ER-associated degradation (ERAD)
machinery, ER/Golgi trafﬁcking, ER folding network, ER calcium
homeostasis, protein degradation pathways (proteasome and
autophagy), among other disturbances [7–9]. These defects trigger
the accumulation of abnormally folded proteins at the ER lumen,
generating a cellular condition known as ER stress [10].
One third of the proteome of most cells is normally folded and
matured in the secretory pathway. Numerous ER resident chaper-
ones, foldases, processing enzymes, and co-factors assemble into
protein folding networks, which alsomediate quality control mech-
anisms. Protein folding is a complex process reﬂected in the failure
to properly fold around 10–30% of newly synthesized proteins,B.V. Open access under CC BY-NC-ND license.
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Fig. 1. The PDI family of proteins. (A) Domain structure of PDI family members is indicated with the following color representation: In blue, catalytic domains a and a0 , in
green and purple, non-catalytic b and b0 domains, respectively. The x-linker between b0 and a0 is shown in orange and transmembrane domains in dark red. (B) Schematic
representation of the protein folding activity of PDI and the redox relay of PDI and ERO1, resulting in the generation of H2O2. PDIOX: oxidized PDI; PDIRED: reduced PDI;
PDIMIXED: PDI with the bound substrate; ERO1OX: oxidized ERO1; ERO1RED: reduced ERO1. PDI domains are colored as shown in (A). (C) Schematic representation of the
function of PDIs at the ER. Brieﬂy, newly synthesized unfolded polypeptides are translocated into the ER. Folding of glycoproteins requires CNX (green) or CRT (light blue) and
ERp57 (purple), the components of the CNX/CRT cycle. Non-glycosylated polypeptides may acquire a folded state by additional protein folding networks, to promote their
folding, including, for example, the participation of PDIA1 or ERp72. ERp44 (dark red) retains client proteins in the ER preventing premature transport to the Golgi until the
folding process is completed (GO). Then, folded proteins are exported through the secretory pathway. Misfolded proteins (STOP) may bind to PDIA1 (orange) and ERp72 (blue)
and retro-translocate to the cytosol via the ERAD pathway, where ERdj5 has an important function in disrupting disulﬁde bonds. Under ER stress conditions, PDIA1 can be
released to the cytosol through activation of BAX and BAK at the ER, targeting the mitochondria. This event triggers apoptosome assembly resulting in cell death. By
modulation of the redox state of calcium channels, such as the IP3 receptor and the calcium pump SERCA, PDIs also control ER calcium release. In addition, abnormal H2O2
production by ERO1 (dark blue) could result in ROS production. These two events may also contribute to trigger mitochondrial outer membrane permeabilization and the
release of cytochrome c (red circles) and the activation of the apoptosome. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
C.I. Andreu et al. / FEBS Letters 586 (2012) 2826–2834 2827
2828 C.I. Andreu et al. / FEBS Letters 586 (2012) 2826–2834which are targeted to the cytosol for proteasome-mediated degra-
dation through the ERAD pathway [11].
ER stress triggers an adaptive program termed the unfolded
protein response (UPR), an integrated signaling cascade that con-
trols the expression of a large spectrum of target genes involved
in almost every aspect of ER physiology [10]. Initially, the UPR in-
creases the folding capacity of the ER through a massive up-regu-
lation of ER chaperones and foldases, including well known
components such as BiP/Grp78, Grp94, calreticulin (CRT), calnexin
(CNX) and several PDI family members [12]. In addition, the re-
moval of misfolded proteins from the ER via ERAD is stimulated
by the UPR by controlling key genes of the pathway, including ER
degradation-enhancing alpha-mannosidase-like 1 (EDEM1) and
Homocysteine-responsive endoplasmic reticulum-resident ubiqui-
tin-like domain protein (HERP) [11,13].
A triade of ER transmembrane proteins operate as stress sen-
sors initiating the UPR. Inositol requiring kinase 1 (IRE1), activat-
ing transcription factor 6 (ATF6), and PKR-like ER kinase (PERK)
monitor ﬂuctuations in the protein folding capacity of the ER
and transduce stress signals to the cytosol and nucleus, control-
ling the expression of speciﬁc transcription factors and signaling
events [13,14]. When UPR adaptive programs are not sufﬁcient
to recover cellular homeostasis, its signaling outputs are shifted
towards the induction of apoptosis [15,16].
PDIs are important targets of the UPR as revealed in numer-
ous gene expression proﬁle studies of cells undergoing ER stress
(see examples in [17–19]). In fact, most proteins trafﬁcking
through the secretory pathway depend on disulﬁde bond forma-
tion and/or isomerization [20]. Hence, PDI family members fulﬁll
key roles as ER foldases by catalyzing disulﬁde reduction (break-
age), formation (oxidation) and isomerization (rearrangement)
thereby promoting native protein folding (Fig. 1B) [21]. Although
some PDI family members have been related to neurodegenera-
tion, their speciﬁc contribution to particular pathological condi-
tions is only beginning to be understood. In this review, we
overview recent ﬁndings indicating important and divergent
roles of PDI family members in PMDs, suggesting their participa-
tion not only in protein folding and quality control, but also in
other processes such as apoptosis, production of reactive oxygen
species (ROS), protein aggregation, cell signaling, and ERAD.3. The protein disulﬁde isomerase family
In this section we discuss the biological andmechanistic aspects
involving PDIs with neurodegenerative diseases. Disulﬁde bonds in
proteins are generated by oxidation of two free thiols originating
from two cysteine residues. The presence of disulﬁde bonds within
(intramolecular) and between (intermolecular) proteins has
important consequences for the structural stability of proteins or
the formation of protein complexes. In addition, disulﬁde bonds
may act as regulatory switches providing a mechanism to control
the function of proteins[21].
PDIs are a large protein family comprised of 21 knownmembers
of the thioredoxin superfamily, classiﬁed based on sequence and
structural homology (reviewed in [22]) (Fig. 1A). In addition to
their function as foldases, PDIs can act as molecular chaperones
by inhibiting the aggregation of unfolded/misfolded proteins at
the ER [20,23]. PDI family members are characterized by a modular
arrangement of thioredoxin-like catalytic a domains and non-cata-
lytic b domains resulting in structural and functional versatility
within the family. The catalytic a domains contain CXXC active-site
motifs that react with thiols of newly synthesized proteins and
determine the redox potential of PDIs and their role as a reductase,
oxidase or isomerase [22]. In an oxidized state, PDIs can transfer
disulﬁdes to the substrate catalyzing its oxidation leading to areduced active site [22]. Conversely, in a reduced state the disulﬁde
of the substrate can be reduced and the PDI active site becomes
oxidized again. The non-catalytic b domains act as stabilizers of
the catalytic a domains and are responsible for substrate recruit-
ment, and provide interaction sites for cofactors [22].
PDI (here termed PDIA1 to differentiate from the general refer-
ral to members of the PDI family) was the ﬁrst PDI family member
identiﬁed and contains four domains, a, b, b0 and a0, arranged in a
U-shaped structure [24]. Studies in yeast indicated an essential
function of PDIs for cell survival [25,26]. Depletion of PDIA1 in
mammalian cells results in a delay in disulﬁde bond formation of
secretory proteins highlighting its vital role in oxidative protein
folding [27]. Despite the extensive progress in our understanding
of the structure and enzymatic properties of PDIA1, little is known
about speciﬁc functions of PDIA1 in vivo. PDIA1 was found to have
the broadest substrate speciﬁcity of the PDI family members inves-
tigated so far [28], a property possibly due to the presence of a
large substrate binding site in the b0 domain recognizing unfolded
proteins. The b domain on the other hand regulates the substrate
binding capacity of the b0 domain which also can be regulated by
an 19 amino acid x-linker region between the b0 and a0 domains
(reviewed in [28]).
ERp57 (also known as Grp58 and PDIA3) displays similar do-
main organization as PDIA1. However, ERp57 is well known as a
key component of the CNX–CRT cycle. As part of a protein complex
with CNX and CRT it is responsible for the folding of highly glycos-
ylated and disulﬁde bond-containing proteins [28]. ERp57 is re-
quired as a scaffolding protein for the assembly of the peptide
loading complex of MHC class I molecules, a function independent
of its enzymatic activity [29]. This alternative function is associated
with a physical interaction with tapasin [30], which requires cova-
lent bonding between them [31,32]. Additional functions of ERp57
as a modulator of ER calcium homeostasis and in STAT3 signaling
have been suggested (reviewed in [33]).
Speciﬁc functions of other PDI family members are poorly
understood. PDIp/PDIA2 displays a similar domain organization
as PDIA1, nevertheless its physiological role is unknown. Ini-
tially, PDIp was found to be expressed in pancreatic acinar cells,
however it is also highly expressed in dopaminergic neurons
suggesting that it supports the increased secretory demand of
these cells [34]. ERp72/PDIA4 on the other hand, has been sug-
gested to compensate for ERp57 deﬁciency in knockout cells
[35]. ERp72 contains three catalytic a domains and two non-cat-
alytic b domains [24]. How ERp72 binds substrates is unclear.
Nevertheless, ERp72 was found to be part of a large complex
of chaperones in the ER including other PDI family members
[36]. For detailed analysis of PDI structure and function see
[28,37]. Overall, despite the fact that the PDI family of proteins
is formed by a large group of highly conserved components, only
a few PDIs have been studied. Very little information is available
about the substrate speciﬁcity of individual PDI family members
and their relation to other components of the ER protein-folding
network or their roles in other cellular locations, such as the
cytosol, mitochondria, or nucleus.
4. Multiple functions of PDIs in neurodegenerative diseases
In the next sections we overview different studies identifying
distinct contributions of PDI family members in diverse
neurodegenerative conditions. Available data suggests important
roles of PDIs in attenuating ER stress and the speciﬁc aggregation
of PMDs-related proteins, in addition to modulating cell death
(both pro- and anti-apoptotic activities) [38], and the local ER re-
dox status, among other important functions (summarized in
Fig. 2A).
AB
Fig. 2. Evidence implicating PDI family of proteins in neurodegenerative diseases. (A) Summary of the most relevant ﬁndings relating PDI family members with multiple
neurodegenerative conditions. (B) Examples of in vivo co-localization between protein inclusions related to the etiology of AD, PD, and ALS with distinct PDI family members.
Data was obtained in human post mortem samples from patients affected with PMDs. Images were originally published in [34,61,65]. Copyright authorization was obtained
from each journal.
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ER stress is a salient feature of most PMDs [7]. The upregulation
of PDIs as part of the general UPR transcriptional responsemay con-
tribute to the reduction of the general overload of misfolded pro-
teins inside the ER. In fact, expression of PDIs has been shown to
protect against ER stress in different experimental settings (exam-
ples in [38–42]). The upregulation of several PDI family members
have been extensively reported in mouse models of PMDs and also
in post-mortem human samples from patients affected with neuro-
degenerative diseases (Fig. 2B). The ﬁrst study describing a func-
tional role of PDIs in the brain was performed more than a decade
ago in a brain ischemia-reperfusion model [43], where through a
proteomic study, PDIA1 was identiﬁed as a major protein induced
in a cell culture model of hypoxia. PDIA1 is highly expressed in
the brain of ischemic rats and its overexpression in vivo resultedin improved neuronal survival upon ischemia reperfusion [43]. Cre-
utzfeldt–Jakob (CJD) disease, a PrD, was the ﬁrst human brain dis-
ease shown to be associated with an upregulation of PDIs. A
proteomic study of sporadic CJD brain tissue showed that ERp57
is induced in the pathology, representing the only consistent hit
of this analysis [44]. We were able to conﬁrm this observation in
sporadic CJD, but also in a case of new variant CJD [45]. Moreover,
we and others, described an increased expression of PDIA1 and
ERp57 in murine models of infectious scrapie-prions [39,45–49].
ERp57 levels directly correlated with the levels of prion misfolding
and inversely correlated with the extent of neuronal damage
[39,50]. Functional studies also indicate that PDIA1 or ERp57
expression protects cells against the toxicity of misfolded PrP
in vitro [39,49].
A large amount of reports link PDIs with the pathogenesis of
ALS. A pioneer proteomic study of symptomatic mutant SOD1
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and ERp57 as the two main proteins upregulated in the spinal cord
[51,52]. Furthermore, PDIA1 overexpression in cell culture protects
against mutant SOD1 neurotoxicity [42]. Consistent with this
observation, increased levels of PDIA1 and ERp57 were found in
the spinal cord and CSF from human sporadic ALS patients [53–
55]. A recent proteomic screening for ALS biomarkers in peripheral
mononuclear cells from ALS patients identiﬁed PDIA1 and ERp57 as
major proteins induced [56]. Remarkably, changes in ERp57
expression had the highest score as a biomarker to monitor disease
progression [56], suggesting its potential use to monitor the effec-
tiveness of clinical trials. In addition, it was suggested that a mem-
ber of the reticulon family, Reticulon-4A (NOGO-A), has a
protective role in an ALS mouse model [57]. In the same study,
therapeutic effects of NOGO-A expression were associated with
intracellular redistribution of PDIA1, indicating a regulatory role
of NOGO-A in PDIA1 function [57].
In two gene expression proﬁle studies of PD cell culture models,
the upregulation of PDIA1 and ERp57 were also identiﬁed as signif-
icant changes of a global ER stress response [58,59]. In addition,
PDIp is induced in a toxicological mouse model of PD, as well as
in brain tissue derived from PD patients [34]. Increased expression
of PDIA1 is also observed in aSynuclein transgenic mice [60]. How-
ever, no studies have addressed the functional contribution of PDIs
to PD in vivo. Augmented levels of PDIA1 were also reported in the
brain of AD patients, co-expressed in cells containing neuroﬁbril-
lary tangles [61,62]. Together these data suggest that augmenta-
tion of the levels of PDIs may represent a protective response to
neurodegenerative conditions associated with abnormal protein
aggregation, contributing to the re-establishment of protein
homeostasis.
4.2. Control of aggregation of disease-related proteins
A few reports have shown that the overexpression of PDIs may
decrease the aggregation of proteins linked to PMDs. For example,
knocking down PDIA1 increased the levels of mutant SOD1 aggre-
gation whereas its overexpression had the opposite effect [42].
These ﬁndings are consistent with the known role of cysteine res-
idues and intermolecular disulﬁde bonding in the aggregation of
mutant SOD1 [63,64]. Moreover, a small molecule that mimics
the active site of PDIs decreased mutant SOD1 aggregation
in vitro [42]. PDIA1 co-localizes with abnormal protein inclusions
associated with sporadic ALS [55]. Furthermore, mutant SOD1 is
found in ER-enriched fractions and a physical interaction between
PDIA1 and mutant SOD1 was described both in vitro and in vivo
[51]. Similar interactions were recently described for another
ALS-linked gene, fused in sarcoma (FUS) [65]. PDIA1 also co-local-
izes with TDP43 in human ALS tissue [55]. Finally, PDIA1-positive
protein inclusions were also described in patients with multiple
system atrophy [66], and Alzheimer’s disease [61,62].
We and others showed that PDIs can physically interact with
misfolded PrP [39,67], and general inhibition of PDI activity with
bacitracin causes the generation of more aggregated PrP [67], con-
sistent with the idea that inter-disulﬁde bond formation is also an
important factor driving prion misfolding [68]. PDIA1 also was
found to prevent aSynuclein aggregation in a cell-free system
[69]. Finally, ERp57 is found in CSF of AD patients physically asso-
ciated with amyloid-b [70], suggesting a role as a carrier protein
that prevents aggregation of the b-amyloid peptide. These few re-
ports propose an interesting scenario where PDIs may not only re-
duce general ER stress levels in PMDs as part of the UPR, but they
could also modulate the aggregation of speciﬁc disease-related
proteins possibly through a direct interaction. However, most of
the data relating PDIs with PMDs so far are correlative with almost
no mechanistic or molecular insights.4.3. The ER redox balance and PDI activity
Sustained maintenance of speciﬁc redox conditions for the for-
mation of correct disulﬁde bonds inside the ER requires equilib-
rium between the oxidized and reduced states of PDIs [71–75].
The ER as an oxidative environment compared to the cytosol favors
protein folding and the formation of disulﬁde bonds between two
cysteine residues by thiol oxidation [76]. Alteration of the ER redox
state is detrimental for normal cell function, and thus well-con-
trolled mechanisms maintain the redox balance inside this orga-
nelle [77]. Yeast and mammalian ERO1 catalyze PDI oxidation
coupled to de novo disulﬁde formation and the reduction of molec-
ular oxygen to hydrogen peroxide (H2O2) [78]. In mammals, ERO1a
is broadly expressed, whereas ERO1b is greatly enriched in the
endocrine pancreas and in immunoglobulin-secreting cells [79–
81]. Under normal physiological conditions, ERO1 probably is the
most important oxidase for disulﬁde formation. Yeasts lacking
ERO1 are not viable [82,83], whereas ERO1a and b double knock-
out mice and cells are viable [81], suggesting that additional path-
ways for disulﬁde formation exist in mammalian cells. In fact,
recently recognized ERO1-independent pathways for the efﬁcient
oxidative folding include enzymes working together with PDI pro-
teins, such as peroxiredoxin (PRDX) 4, glutathione peroxidase
(GPX7 and GPX8), quiescin sulfhydryl oxidase (QSOX) and vitamin
K epoxide reductase (VKOR) (reviewed in [84]). Other studies also
suggest that small molecules like H2O2, glutathione disulﬁde
(GSSG) or dehydroascorbate directly oxidize cysteines in PDIA1
and substrate proteins to form disulﬁdes bonds (reviewed in
[84]). To prevent hyper-oxidizing conditions and overproduction
of ROS different redox buffers operate inside the ER, where GSH
is maintained at high levels [72]. The existence of additional path-
ways to generate disulﬁde bonds in proteins in the ER of mamma-
lian cells suggests that PDIs may function more speciﬁcally to
control folding of selected client proteins.
The accumulation of unfolded proteins in the ER lumen is sufﬁ-
cient to produce ROS [85,86], suggesting a vicious cycle of ER stress
and local oxidative stress ﬁnally leading to cell death when unre-
solved [87]. In fact, the efﬁciency of ER protein folding and secre-
tion can be enhanced by antioxidants [88]. Thus, uncontrolled ER
stress or an imbalance between PDIs/ERO1 and other redox buffer-
ing systems may contribute to the generation of oxidative stress in
neurodegenerative diseases, a hypothesis that remains to be fur-
ther explored. On the other hand, an altered ER redox status could
explain the occurrence of ER stress in some PMDs through direct
inhibition of PDIs function (see next section).
4.4. Inactivation of PDIs by S-nitrosylation
Enhanced production of ROS has been proposed to be the cause
of ER stress in pharmacological models of PD in vitro [89]. This
phenomenon correlates with the oxidation of ERp57, leading to
accumulation of high molecular weight ERp57-containing aggre-
gates [90]. Accumulating evidence indicates that oxidative stress
actually directly alters the activity of PDIs in many human diseases
(reviewed in [91]). For example, S-nitrosylation of PDIA1 was ini-
tially described in brain tissue derived from PD and AD [38]. This
chemical modiﬁcation inactivates PDIA1 activity, possibly trigger-
ing ER stress in addition to eliminating its anti-apoptotic activity
[38]. Similarly, PDIA1 S-nitrosylation is observed in spinal cord tis-
sue derived from human ALS cases and mouse models of the dis-
ease [42]. Similarly, PDIA1 S-nitrosylation was recently reported
in a PrD model [49]. One study also suggested that nitrosative
stress could also trigger S-glutathionylation of PDIA1 [92]. Overall,
many correlative reports have shown the simultaneous occurrence
of ER stress and oxidative stress in PMDs in vivo (see examples in
[93,94]). However, most of the available in vivo observations are
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neurodegeneration remains to be established with more direct
approaches.
4.5. Pro-apoptotic role of PDIs
Chronic or irreversible ER stress triggers apoptosis [16], where
apoptotic signals converge into the activation of the main intrinsic
death pathway at themitochondria through activation of pro-apop-
totic BCL-2 family members [13]. Activation of BAX and BAK is key
to induce ER stress-mediated apoptosis facilitated by the release of
cytochrome c and the assembly of the apoptosome [95]. BAX and
BAK are also located at the ER membrane, where they control ER
calcium homeostasis [95,96] and UPR signaling [97,98]. Remark-
ably, a recent report indicates that BCL-2 proteins also regulate
the permeability of the ER membrane to luminal proteins during
apoptosis, associated with the release of ER chaperones including
PDIA1 and BiP [99]. This study suggested that PDIA1 might have a
direct function in regulating apoptosis signaling.
A small molecule screening for compounds that decrease mu-
tant huntingtin toxicity identiﬁed ﬁve molecules that all target
and inhibit PDIA1 and ERp57 [100]. These unexpected ﬁndings
were conﬁrmed by direct manipulation of PDIA1 and ERp57 levels
in models of HD and AD in the same study [100]. Remarkably,
PDIA1 was shown to induce mitochondrial-outer membrane per-
meabilization in a BAK-dependent manner, triggering the canoni-
cal apoptosis pathway (Fig. 1C). This phenomenon was associated
with the accumulation of PDIs in membrane contact sites between
ER and mitochondria [100]. This novel pro-apoptotic function of
PDIs may represent a new link between protein misfolding and cell
death that contrasts with the known role of PDIs in alleviating ER
stress and promoting cell survival (dual function).
4.6. Other possible biological functions of PDIs in neurodegeneration?
PDIs are located in many subcellular compartments, including
the ER, cytosol, mitochondria, nucleus, plasma membrane as well
as the extracellular space (reviewed in [101]). Their ubiquitous cel-
lular distribution highlights their direct or indirect participation in
many biological processes. Under various physiological conditions
PDIs may modulate the structure and function of individual client
proteins at distinct subcellular locations via their chaperone, fol-
dase or isomerase activity. Owing to their ER localization, PDIs af-
fect the folding of many proteins that transit through the secretory
pathway which may depend on the cell type affected. ERp57 was
described to participate in signaling events from the plasma mem-
brane as well as in regulatory events in the nucleus where it was
found to interact with several transcription factors and with DNA
itself [33]. These observations suggest many additional functions
of PDIs in the maintenance of cellular homeostasis. ERdj5 has a
central role in ERAD, where it catalyzes the disruption of disulﬁde
bonds to allow the retro-translocation of proteins to the cytosol for
degradation [102]. This opens the possibility that the effects of
PDIs on the aggregation of PMDs-related proteins may be related
to enhanced degradation. PDIs also modulate the activity of ER cal-
cium channels and pumps [103,104], which may impact diverse
physiological processes dependent on calcium such as mitochon-
drial metabolism and apoptosis. It remains to be determined if
all these alternative functions of PDIs may also contribute to neu-
rodegeneration in PMDs.
4.7. Studies of PDIs function in vivo
The function of PDI family of proteins is poorly understood
in vivo. A few knockout mouse models for PDIs have been de-
scribed to date, including ERp57, ERdj5 and AGR2 [29,105–108].Full ERp57 deﬁciency is lethal in mice at embryonic day 13.5, pos-
sibly due to STAT3 signaling modulation [109]. In this study, dele-
tion of ERp57 had no effect on ER morphology, ER stress sensitivity,
apoptosis or the expression of other ER chaperones in ERp57 deﬁ-
cient mouse embryonic ﬁbroblast (MEF) cells [109]. B-cell speciﬁc
ERp57 knockout mice show decreased MHC class I expression and
suboptimal peptide loading [29]. Unexpectedly, B cells deﬁcient for
ERp57 produce normal levels of immunoglobulin, a highly glycos-
ylated protein containing several disulﬁde bonds. Deletion of
ERp57 in intestinal cells showed that enterocytes fail to display
steroid hormone-stimulated calcium responses [105].
In ERdj5 knockout mice show increased levels of ER stress
markers in the salivary gland [108]. ERdj5 expression alleviates
ER stress triggered by a-amylase overexpression [108]. Anterior
gradient homolog 2 (AGR2)/PDIA17 deﬁciency in mice drastically
alters intestinal homeostasis [107]. AGR2 knockout mice are viable,
but show decreased levels of mucin, an essential component of the
protective mucus in the intestine. These mice also presented
abnormal Paneth cell morphology with increased levels of ER
stress. AGR2 deﬁcient animals develop severe colitis [107]. Another
study also showed that AGR2 deﬁcient mice are more susceptible
to colitis due to reduced production of intestinal mucin [106]. Re-
lated observations were also described on loss-of-function experi-
ments in zebraﬁsh [110]. AGR2 function has been also related to
the metastatic capacity of pancreatic cancer in vivo [111]. Studies
of ERp5/PDIA6 in zebraﬁsh indicated an interesting developmental
function in maintaining the asymmetry of several organs including
the brain [112].
Deﬁciency in the ER disulﬁde oxidase ERO1a does not induce
clear spontaneous phenotypes, whereas ERO1b deﬁciency alters
pro-insulin folding, triggering glucose intolerance [81]. As men-
tioned, ERO1a and ERO1b double deﬁcient animals are viable, hav-
ing normal secretion of immunoglobulins [81], which is consistent
with the existence of independent pathways for disulﬁde bond for-
mation. Most attempts of generating knockout mouse models for
ER chaperones failed, because deﬁciency lead to embryonic lethal-
ity, due to their vital roles during embryonic development [113].
Interestingly, knockout mice for CNX [114], BiP [115], and Sil1
[116], a nucleotide exchange factor for BiP, have revealed impor-
tant roles of these proteins in the maintenance of protein homeo-
stasis in the nervous system. However, to date the possible impact
of PDI family members on brain function, as well as their contribu-
tion to motor or cognitive functions of the CNS, remains fully unex-
plored. It will be interesting to deﬁne if PDIs are involved in the
synthesis and secretion of speciﬁc neurotransmitters, which could
have a broad impact on neuronal function, an important aspect to
consider for future clinical use of PDI inhibitors.5. Concluding remarks
The role of the PDI family in the CNS remains highly elusive. In
this review we discussed most evidence suggesting the involve-
ment of these enzymes in neurodegenerative diseases. PDIs are a
large family of foldases with complex yet poorly characterized
functions with emerging roles in PMDs (Fig. 2). Of note, PDIs are
linked to other important diseases such as cancer and infectious
diseases, including HIV-AIDS, Hepatitis and Chlamydia infections.
The broad involvement of PDIs in human pathologies underlines
their importance in fundamental processes, and highlights the
need for a better understanding of their biological function, which
is crucial to evaluate their use as possible targets for disease inter-
vention. Small molecules to inhibit PDI activity or gene therapy ap-
proaches for ‘‘gain of function’’ may have speciﬁc applications
depending on the disease context. However, the ﬁeld clearly needs
to advance into detailed in vivo validation to speciﬁcally identify
2832 C.I. Andreu et al. / FEBS Letters 586 (2012) 2826–2834the contribution of distinct PDI family members to particular path-
ological conditions using conditional knockout mouse models. In
addition, a better deﬁnition of how ER protein-folding networks
are arranged and what are their substrate speciﬁcities is necessary
to move forward into therapeutic applications.
Monitoring the expression of distinct PDI family members or an
overall PDI network signature in body ﬂuids may also serve as an
important tool for early disease diagnosis due to the fact that
PDIA1 and ERp57 are present in CSF and blood of ALS patients
[56] and have been identiﬁed as top hits in several proteomic
screenings of human diseases. ERp57 and CRT are also upregulated
on the cell surface of cancer cells, which has been exploited for
immunotherapy [117]. Inhibitors of PDIs also represent efﬁcient
anticancer compounds [118,119]. Thus, we believe that cancer re-
search may provide interesting compounds in the near future to
manipulate PDIs in PMDs.
In summary, the information discussed here demonstrates the
signiﬁcance of PDIs as potential targets for new treatments and
the potential use of PDIs as biomarkers for diagnosis and prognosis
of neurodegenerative diseases. Since PDIs play key roles in diverse
cellular contexts, the generation of more speciﬁc compounds to
target distinct PDI family members will be of high relevance to pre-
vent potential systemic effects of chronic drug administration. To
solve this issue, gene therapy represents a reliable option to
manipulate speciﬁc PDI-family members in a disease context, lo-
cally in the affected tissue. This concept has been already probed
in animal models of brain and cardiomyocyte ischemia [43,120].
The development of new mouse models to study the biology of
PDI family members in speciﬁc tissues will provide valuable infor-
mation to deﬁne their function in physiology and disease. Finally,
due to the fact that alterations in PDIs function is emerging as an
important factor in many PMDs, the possible occurrence of genetic
mutations in PDI genes as part of the etiology of PMDs represents
an interesting open question to be explored through genetic
screening in the human population.
Acknowledgements
This work was funded by the Muscular Dystrophy Association
and ALS Therapy Alliance, and FONDECYT No. 1100176 (to C.H.),
and a postdoctoral FONDECYT fellowship No. 3110067 (to U.W.).
We also received support from FONDAP Grant No. 15010006, Mil-
lennium Institute No. P09-015-F, Ring Initiative Act 1109, Alzhei-
mer Association, North American Spine Society, and the Michael
J. Fox Foundation for Parkinson research (to C.H.), and a CONICYT
and FEBA Foundation PhD fellowships (M.T.).
References
[1] Benham, A.M. (2012) The protein disulﬁde isomerase family: key players in
health and disease. Antioxid. Redox Signal. 16, 781–789.
[2] Soto, C. (2003) Unfolding the role of protein misfolding in neurodegenerative
diseases. Nat. Rev. Neurosci. 4, 49–60.
[3] Saxena, S. and Caroni, P. (2011) Selective neuronal vulnerability in
neurodegenerative diseases: from stressor thresholds to degeneration.
Neuron 71, 35–48.
[4] Rubinsztein, D.C. (2006) The roles of intracellular protein-degradation
pathways in neurodegeneration. Nature 443, 780–786.
[5] Haass, C. and Selkoe, D.J. (2007) Soluble protein oligomers in
neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide.
Nat. Rev. Mol. Cell Biol. 8, 101–112.
[6] Jellinger, K.A. (2010) Basic mechanisms of neurodegeneration: a critical
update. J. Cell. Mol. Med. 14, 457–487.
[7] Matus, S., Glimcher, L.H. and Hetz, C. (2011) Protein folding stress in
neurodegenerativediseases:aglimpseintotheER.Curr.Opin.CellBiol.23,239–252.
[8] Vidal, R., Caballero, B., Couve, A. and Hetz, C. (2011) Converging pathways in
the occurrence of endoplasmic reticulum (ER) stress in Huntington’s disease.
Curr. Mol. Med. 11, 1–12.
[9] Nassif, M., Matus, S., Castillo, K. and Hetz, C. (2010) Amyotrophic lateral
sclerosis pathogenesis: a journey through the secretory pathway. Antioxid.
Redox Signal. 13, 1955–1989.[10] Hetz, C. (2012) The unfolded protein response: controlling cell fate decisions
under ER stress and beyond. Nat. Rev. Mol. Cell Biol. 13, 89–102.
[11] Vembar, S.S. and Brodsky, J.L. (2008) One step at a time: endoplasmic
reticulum-associated degradation. Nat. Rev. Mol. Cell Biol. 9, 944–957.
[12] Schroder, M. and Kaufman, R.J. (2005) ER stress and the unfolded protein
response. Mutat. Res. 569, 29–63.
[13] Hetz, C., Martinon, F., Rodriguez, D. and Glimcher, L.H. (2011) The unfolded
protein response: integrating stress signals through the stress sensor
IRE1{alpha}. Physiol. Rev. 91, 1219–1243.
[14] Walter, P. and Ron, D. (2011) The unfolded protein response: from stress
pathway to homeostatic regulation. Science 334, 1081–1086.
[15] Woehlbier, U. and Hetz, C. (2011) Modulating stress responses by the
UPRosome: a matter of life and death. Trends Biochem. Sci. 36, 329–337.
[16] Tabas, I. and Ron, D. (2011) Integrating the mechanisms of apoptosis induced
by endoplasmic reticulum stress. Nat. Cell Biol. 13, 184–190.
[17] Lee, A.H., Iwakoshi, N.N. and Glimcher, L.H. (2003) XBP-1 regulates a subset
of endoplasmic reticulum resident chaperone genes in the unfolded protein
response. Mol. Cell. Biol. 23, 7448–7459.
[18] Acosta-Alvear, D. et al. (2007) XBP1 controls diverse cell type- and condition-
speciﬁc transcriptional regulatory networks. Mol. Cell 27, 53–66.
[19] Harding, H.P. et al. (2003) An integrated stress response regulates amino acid
metabolism and resistance to oxidative stress. Mol. Cell 11, 619–633.
[20] Hatahet, F. and Ruddock, L.W. (2009) Protein disulﬁde isomerase: a critical
evaluation of its function in disulﬁde bond formation. Antioxid. Redox Signal.
11, 2807–2850.
[21] Feige, M.J. and Hendershot, L.M. (2011) Disulﬁde bonds in ER protein folding
and homeostasis. Curr. Opin. Cell Biol. 23, 167–175.
[22] Appenzeller-Herzog, C. and Ellgaard, L. (2008) The human PDI family:
versatility packed into a single fold. Biochim. Biophys. Acta 1783, 535–548.
[23] Wilkinson, B. and Gilbert, H.F. (2004) Protein disulﬁde isomerase. Biochim.
Biophys. Acta 1699, 35–44.
[24] Kozlov, G., Maattanen, P., Thomas, D.Y. and Gehring, K. (2010) A structural
overview of the PDI family of proteins. FEBS J. 277, 3924–3936.
[25] LaMantia, M., Miura, T., Tachikawa, H., Kaplan, H.A., Lennarz, W.J. and
Mizunaga, T. (1991) Glycosylation site binding protein and protein disulﬁde
isomerase are identical and essential for cell viability in yeast. Proc. Natl.
Acad. Sci. U S A 88, 4453–4457.
[26] Solovyov, A., Xiao, R. and Gilbert, H.F. (2004) Sulfhydryl oxidation, not
disulﬁde isomerization, is the principal function of protein disulﬁde
isomerase in yeast Saccharomyces cerevisiae. J. Biol. Chem. 279, 34095–34100.
[27] Rutkevich, L.A., Cohen-Doyle, M.F., Brockmeier, U. and Williams, D.B. (2010)
Functional relationship between protein disulﬁde isomerase family members
during the oxidative folding of human secretory proteins. Mol. Biol. Cell 21,
3093–3105.
[28] Rutkevich, L.A. and Williams, D.B. (2011) Participation of lectin chaperones
and thiol oxidoreductases in protein folding within the endoplasmic
reticulum. Curr. Opin. Cell Biol. 23, 157–166.
[29] Garbi,N., Tanaka, S.,Momburg, F. andHammerling,G.J. (2006) Impairedassembly
of themajor histocompatibility complex class I peptide-loading complex inmice
deﬁcient in the oxidoreductase ERp57. Nat. Immunol. 7, 93–102.
[30] Dong, G., Wearsch, P.A., Peaper, D.R., Cresswell, P. and Reinisch, K.M. (2009)
Insights into MHC class I peptide loading from the structure of the tapasin-
ERp57 thiol oxidoreductase heterodimer. Immunity 30, 21–32.
[31] Kienast, A., Preuss, M., Winkler, M. and Dick, T.P. (2007) Redox regulation of
peptide receptivity of major histocompatibility complex class I molecules by
ERp57 and tapasin. Nat. Immunol. 8, 864–872.
[32] Garbi, N., Hammerling, G. and Tanaka, S. (2007) Interaction of ERp57 and
tapasin in the generation of MHC class I-peptide complexes. Curr. Opin.
Immunol. 19, 99–105.
[33] Turano, C., Gaucci, E., Grillo, C. and Chichiarelli, S. (2011) ERp57/GRP58: a
protein with multiple functions. Cell. Mol. Biol. Lett. 16, 539–563.
[34] Conn, K.J., Gao, W., McKee, A., Lan, M.S., Ullman, M.D., Eisenhauer, P.B., Fine,
R.E. and Wells, J.M. (2004) Identiﬁcation of the protein disulﬁde isomerase
family member PDIp in experimental Parkinson’s disease and Lewy body
pathology. Brain Res. 1022, 164–172.
[35] Solda, T., Garbi, N., Hammerling, G.J. and Molinari, M. (2006) Consequences of
ERp57 deletion on oxidative folding of obligate and facultative clients of the
calnexin cycle. J. Biol. Chem. 281, 6219–6226.
[36] Meunier, L., Usherwood, Y.K., Chung, K.T. and Hendershot, L.M. (2002) A
subset of chaperones and folding enzymes form multiprotein complexes in
endoplasmic reticulum to bind nascent proteins. Mol. Biol. Cell 13, 4456–
4469.
[37] Wang, C., Li, W., Ren, J., Fang, J., Ke, H., Gong, W., Feng, W. and Wang, C.C.
(2012) Structural insights into the redox-regulated dynamic conformations
of human protein disulﬁde isomerase, Antioxid Redox Signal.
[38] Uehara, T. et al. (2006) S-nitrosylated protein-disulphide isomerase links
protein misfolding to neurodegeneration. Nature 441, 513–517.
[39] Hetz, C., Russelakis-Carneiro, M., Walchli, S., Carboni, S., Vial-Knecht, E.,
Maundrell, K., Castilla, J. and Soto, C. (2005) The disulﬁde isomerase Grp58 is
a protective factor against prion neurotoxicity. J. Neurosci. 25, 2793–2802.
[40] Vekich, J.A., Belmont, P.J., Thuerauf, D.J. and Glembotski, C.C. (2012) Protein
disulﬁde isomerase-associated 6 is an ATF6-inducible ER stress response
protein that protects cardiac myocytes from ischemia/reperfusion-mediated
cell death. J. Mol. Cell. Cardiol..
[41] Sullivan, D.C., Huminiecki, L., Moore, J.W., Boyle, J.J., Poulsom, R., Creamer, D.,
Barker, J. and Bicknell, R. (2003) EndoPDI, a novel protein-disulﬁde
C.I. Andreu et al. / FEBS Letters 586 (2012) 2826–2834 2833isomerase-like protein that is preferentially expressed in endothelial cells
acts as a stress survival factor. J. Biol. Chem. 278, 47079–47088.
[42] Walker, A.K., Farg, M.A., Bye, C.R., McLean, C.A., Horne, M.K. and Atkin, J.D.
(2010) Protein disulphide isomerase protects against protein aggregation and
is S-nitrosylated in amyotrophic lateral sclerosis. Brain Res. 133, 105–116.
[43] Tanaka, S., Uehara, T. and Nomura, Y. (2000) Up-regulation of protein-
disulﬁde isomerase in response to hypoxia/brain ischemia and its protective
effect against apoptotic cell death. J. Biol. Chem. 275, 10388–10393.
[44] Yoo, B.C., Krapfenbauer, K., Cairns, N., Belay, G., Bajo, M. and Lubec, G. (2002)
Overexpressed protein disulﬁde isomerase in brains of patients with sporadic
Creutzfeldt-Jakob disease. Neurosci. Lett. 334, 196–200.
[45] Hetz, C., Russelakis-Carneiro, M., Maundrell, K., Castilla, J. and Soto, C. (2003)
Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of
pathological prion protein. EMBO J. 22, 5435–5445.
[46] Hetz, C., Lee, A.H., Gonzalez-Romero, D., Thielen, P., Castilla, J., Soto, C. and
Glimcher, L.H. (2008) Unfolded protein response transcription factor XBP-1
does not inﬂuence prion replication or pathogenesis. Proc. Natl. Acad. Sci. U S
A 105, 757–762.
[47] Steele, A.D., Hetz, C., Yi, C.H., Jackson, W.S., Borkowski, A.W., Yuan, J.,
Wollmann, R.H. and Lindquist, S. (2007) Prion pathogenesis is independent of
caspase-12. Prion 1, 243–247.
[48] Rane, N.S., Kang, S.W., Chakrabarti, O., Feigenbaum, L. and Hegde, R.S. (2008)
Reduced translocation of nascent prion protein during ER stress contributes
to neurodegeneration. Dev. Cell 15, 359–370.
[49] Wang, S.B. et al. (2012) Protein disulﬁde isomerase regulates endoplasmic
reticulum stress and the apoptotic process during prion infection and PrP
mutant-induced cytotoxicity. PLoS One 7, e38221.
[50] Hetz, C.A. and Soto, C. (2006) Emerging roles of the unfolded protein response
signaling in physiology and disease. Curr. Mol. Med. 6, 1.
[51] Atkin, J.D. et al. (2006) Induction of the unfolded protein response in familial
amyotrophic lateral sclerosis and association of protein-disulﬁde isomerase
with superoxide dismutase 1. J. Biol. Chem. 281, 30152–30165.
[52] Massignan, T. et al. (2007) Proteomic analysis of spinal cord of
presymptomatic amyotrophic lateral sclerosis G93A SOD1 mouse. Biochem.
Biophys. Res. Commun. 353, 719–725.
[53] Atkin, J.D., Farg, M.A., Walker, A.K., McLean, C., Tomas, D. and Horne, M.K.
(2008) Endoplasmic reticulum stress and induction of the unfolded protein
response in human sporadic amyotrophic lateral sclerosis. Neurobiol. Dis. 30,
400–407.
[54] Hetz, C. et al. (2009) XBP-1 deﬁciency in the nervous system protects against
amyotrophic lateral sclerosis by increasing autophagy. Genes Dev. 23, 2294–2306.
[55] Honjo, Y. et al. (2011) Protein disulﬁde isomerase-immunopositive inclusions
in patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 12,
444–450.
[56] Nardo, G. et al. (2011) Amyotrophic lateral sclerosis multiprotein biomarkers
in peripheral blood mononuclear cells. PLoS One 6, e25545.
[57] Yang, Y.S., Harel, N.Y. and Strittmatter, S.M. (2009) Reticulon-4A (Nogo-A)
redistributes protein disulﬁde isomerase to protect mice from SOD1-
dependent amyotrophic lateral sclerosis. J. Neurosci. 29, 13850–13859.
[58] Ryu, E.J., Harding, H.P., Angelastro, J.M., Vitolo, O.V., Ron, D. and Greene, L.A.
(2002) Endoplasmic reticulum stress and the unfolded protein response in
cellular models of Parkinson’s disease. J. Neurosci. 22, 10690–10698.
[59] Holtz, W.A. and O’Malley, K.L. (2003) Parkinsonian mimetics induce aspects
of unfolded protein response in death of dopaminergic neurons. J. Biol. Chem.
278, 19367–19377.
[60] Colla, E., Coune, P., Liu, Y., Pletnikova, O., Troncoso, J.C., Iwatsubo, T.,
Schneider, B.L. and Lee, M.K. (2012) Endoplasmic reticulum stress is
important for the manifestations of alpha-synucleinopathy in vivo. J.
Neurosci. 32, 3306–3320.
[61] Honjo, Y., Ito, H., Horibe, T., Takahashi, R. and Kawakami, K. (2010) Protein
disulﬁde isomerase-immunopositive inclusions in patients with Alzheimer
disease. Brain Res. 1349, 90–96.
[62] Honjo, Y., Ito, H., Horibe, T., Shimada, H., Nakanishi, A., Mori, H., Takahashi, R.
and Kawakami, K. (2012) Derlin-1-immunopositive inclusions in patients
with Alzheimer’s disease. Neuroreport 23, 611–615.
[63] Karch, C.M., Prudencio, M., Winkler, D.D., Hart, P.J. and Borchelt, D.R. (2009)
Role of mutant SOD1 disulﬁde oxidation and aggregation in the pathogenesis
of familial ALS. Proc. Natl. Acad. Sci. U S A 106, 7774–7779.
[64] Niwa, J. et al. (2007) Disulﬁde bond mediates aggregation, toxicity, and
ubiquitylation of familial amyotrophic lateral sclerosis-linked mutant SOD1.
J. Biol. Chem. 282, 28087–28095.
[65] Farg, M.A. et al. (2012) Mutant FUS induces endoplasmic reticulum stress in
amyotrophic lateral sclerosis and interacts with protein disulﬁde-isomerase.
Neurobiol Aging.
[66] Honjo, Y., Ito, H., Horibe, T., Takahashi, R. and Kawakami, K. (2011) Protein
disulﬁde isomerase immunopositive glial cytoplasmic inclusions in patients
with multiple system atrophy. Int. J. Neurosci. 121, 543–550.
[67] Watts, J.C. et al. (2009) Interactome analyses identify ties of PrP and its
mammalian paralogs to oligomannosidic N-glycans and endoplasmic
reticulum-derived chaperones. PLoS Pathog. 5, e1000608.
[68] Welker, E., Wedemeyer, W.J. and Scheraga, H.A. (2001) A role for
intermolecular disulﬁde bonds in prion diseases? Proc. Natl. Acad. Sci. U S
A 98, 4334–4336.
[69] Cheng, H., Wang, L. and Wang, C.C. (2010) Domain a0 of protein disulﬁde
isomerase plays key role in inhibiting alpha-synuclein ﬁbril formation. Cell
Stress Chaperones 15, 415–421.[70] Erickson, R.R., Dunning, L.M., Olson, D.A., Cohen, S.J., Davis, A.T., Wood, W.G.,
Kratzke, R.A. and Holtzman, J.L. (2005) In cerebrospinal ﬂuid ER chaperones
ERp57 and calreticulin bind beta-amyloid. Biochem. Biophys. Res. Commun.
332, 50–57.
[71] Appenzeller-Herzog, C., Riemer, J., Christensen, B., Sorensen, E.S. and Ellgaard,
L. (2008) A novel disulphide switch mechanism in Ero1alpha balances ER
oxidation in human cells. EMBO J. 27, 2977–2987.
[72] Appenzeller-Herzog, C., Riemer, J., Zito, E., Chin, K.T., Ron, D., Spiess, M. and
Ellgaard, L. (2010) Disulphide production by Ero1alpha-PDI relay is rapid and
effectively regulated. EMBO J. 29, 3318–3329.
[73] Chakravarthi, S. and Bulleid, N.J. (2004) Glutathione is required to regulate
the formation of native disulﬁde bonds within proteins entering the
secretory pathway. J. Biol. Chem. 279, 39872–39879.
[74] Jessop, C.E. and Bulleid, N.J. (2004) Glutathione directly reduces an
oxidoreductase in the endoplasmic reticulum of mammalian cells. J. Biol.
Chem. 279, 55341–55347.
[75] Molteni, S.N., Fassio, A., Ciriolo, M.R., Filomeni, G., Pasqualetto, E., Fagioli, C.
and Sitia, R. (2004) Glutathione limits Ero1-dependent oxidation in the
endoplasmic reticulum. J. Biol. Chem. 279, 32667–32673.
[76] Hwang, C., Sinskey, A.J. and Lodish, H.F. (1992) Oxidized redox state of
glutathione in the endoplasmic reticulum. Science 257, 1496–1502.
[77] Higa, A. and Chevet, E. (2012) Redox signaling loops in the unfolded protein
response. Cell Signal. 24, 1548–1555.
[78] Tavender, T.J. and Bulleid, N.J. (2010) Molecular mechanisms regulating
oxidative activity of the Ero1 family in the endoplasmic reticulum. Antioxid.
Redox Signal. 13, 1177–1187.
[79] Dias-Gunasekara, S. et al. (2005) Tissue-speciﬁc expression and dimerization
of the endoplasmic reticulum oxidoreductase Ero1beta. J. Biol. Chem. 280,
33066–33075.
[80] Pagani, M., Fabbri, M., Benedetti, C., Fassio, A., Pilati, S., Bulleid, N.J., Cabibbo,
A. and Sitia, R. (2000) Endoplasmic reticulum oxidoreductin 1-lbeta (ERO1-
Lbeta), a human gene induced in the course of the unfolded protein response.
J. Biol. Chem. 275, 23685–23692.
[81] Zito, E., Chin, K.T., Blais, J., Harding, H.P. and Ron, D. (2010) ERO1-beta, a
pancreas-speciﬁc disulﬁde oxidase, promotes insulin biogenesis and glucose
homeostasis. J Cell Biol 188, 821–832.
[82] Frand, A.R. and Kaiser, C.A. (1998) The ERO1 gene of yeast is required for
oxidation of protein dithiols in the endoplasmic reticulum.Mol. Cell 1, 161–170.
[83] Pollard, M.G., Travers, K.J. and Weissman, J.S. (1998) Ero1p: a novel and
ubiquitous protein with an essential role in oxidative protein folding in the
endoplasmic reticulum. Mol. Cell 1, 171–182.
[84] Bulleid, N.J. and Ellgaard, L. (2011) Multiple ways to make disulﬁdes. Trends
Biochem. Sci. 36, 485–492.
[85] Merksamer, P.I., Trusina, A. and Papa, F.R. (2008) Real-time redox
measurements during endoplasmic reticulum stress reveal interlinked
protein folding functions. Cell Death Differ. 135, 933–947.
[86] Enyedi, B., Varnai, P. and Geiszt, M. (2010) Redox state of the endoplasmic
reticulum is controlled by Ero1L-alpha and intraluminal calcium. Antioxid.
Redox Signal. 13, 721–729.
[87] Malhotra, J.D. and Kaufman, R.J. (2007) Endoplasmic reticulum stress and
oxidative stress: a vicious cycle or a double-edged sword? Antioxid. Redox
Signal. 9, 2277–2293.
[88] Malhotra, J.D., Miao, H., Zhang, K., Wolfson, A., Pennathur, S., Pipe, S.W. and
Kaufman, R.J. (2008) Antioxidants reduce endoplasmic reticulum stress and
improve protein secretion. Proc. Natl. Acad. Sci. U S A 105, 18525–18530.
[89] Holtz, W.A., Turetzky, J.M., Jong, Y.J. and O’Malley, K.L. (2006) Oxidative
stress-triggered unfolded protein response is upstream of intrinsic cell death
evoked by parkinsonian mimetics. J. Neurochem. 99, 54–69.
[90] Kim-Han, J.S. and O’Malley, K.L. (2007) Cell stress induced by the
parkinsonian mimetic, 6-hydroxydopamine, is concurrent with oxidation of
the chaperone, ERp57, and aggresome formation. Antioxid. Redox Signal. 9,
2255–2264.
[91] Nakamura, T. and Lipton, S.A. (2011) Redox modulation by S-nitrosylation
contributes to protein misfolding, mitochondrial dynamics, and neuronal
synaptic damage in neurodegenerative diseases. Cell Death Differ. 18, 1478–1486.
[92] Townsend, D.M., Manevich, Y., He, L., Xiong, Y., Bowers Jr., R.R., Hutchens, S.
and Tew, K.D. (2009) Nitrosative stress-induced s-glutathionylation of
protein disulﬁde isomerase leads to activation of the unfolded protein
response. Cancer Res. 69, 7626–7634.
[93] Ilieva, E.V. et al. (2007) Oxidative and endoplasmic reticulum stress interplay
in sporadic amyotrophic lateral sclerosis. Brain Res. 130, 3111–3123.
[94] Brown, A.R., Rebus, S., McKimmie, C.S., Robertson, K., Williams, A. and
Fazakerley, J.K. (2005) Gene expression proﬁling of the preclinical scrapie-
infected hippocampus. Biochem. Biophys. Res. Commun. 334, 86–95.
[95] Scorrano, L., Oakes, S.A., Opferman, J.T., Cheng, E.H., Sorcinelli, M.D., Pozzan,
T. and Korsmeyer, S.J. (2003) BAX and BAK regulation of endoplasmic
reticulum Ca2+: a control point for apoptosis. Science 300, 135–139.
[96] Zong, W.X., Li, C., Hatzivassiliou, G., Lindsten, T., Yu, Q.C., Yuan, J. and
Thompson, C.B. (2003) Bax and Bak can localize to the endoplasmic reticulum
to initiate apoptosis. J Cell Biol 162, 59–69.
[97] Hetz, C. et al. (2006) Proapoptotic BAX and BAK modulate the unfolded
protein response by a direct interaction with IRE1alpha. Science 312, 572–
576.
[98] Rodriguez, D.A. et al. (2012) BH3-only proteins are part of a regulatory
network that control the sustained signalling of the unfolded protein
response sensor IRE1alpha. EMBO J. 31, 2322–2335.
2834 C.I. Andreu et al. / FEBS Letters 586 (2012) 2826–2834[99] Wang, X., Olberding, K.E., White, C. and Li, C. (2011) Bcl-2 proteins regulate
ER membrane permeability to luminal proteins during ER stress-induced
apoptosis. Cell Death Differ. 18, 38–47.
[100] Hoffstrom, B.G., Kaplan, A., Letso, R., Schmid, R.S., Turmel, G.J., Lo, D.C. and
Stockwell, B.R. (2010) Inhibitors of protein disulﬁde isomerase suppress
apoptosis induced by misfolded proteins. Nat. Chem Biol. 6, 900–906.
[101] Turano, C., Coppari, S., Altieri, F. andFerraro,A. (2002) Proteins of the PDI family:
unpredicted non-ER locations and functions. J. Cell. Physiol. 193, 154–163.
[102] Hagiwara, M. and Nagata, K. (2012) Redox-dependent protein quality control
in the endoplasmic reticulum: folding to degradation. Antioxid. Redox Signal.
16, 1119–1128.
[103] Li, Y. and Camacho, P. (2004) Ca2+-dependent redox modulation of SERCA 2b
by ERp57. J Cell Biol 164, 35–46.
[104] Prins, D., Groenendyk, J., Touret, N. and Michalak, M. (2011) Modulation of
STIM1 and capacitative Ca2+ entry by the endoplasmic reticulum luminal
oxidoreductase ERp57. EMBO Rep. 12, 1182–1188.
[105] Nemere, I., Garbi, N., Hammerling, G.J. and Khanal, R.C. (2010) Intestinal cell
calcium uptake and the targeted knockout of the 1,25D3-MARRS
(membrane-associated, rapid response steroid-binding) receptor/PDIA3/
Erp57. J. Biol. Chem. 285, 31859–31866.
[106] Park, S.W., Zhen, G., Verhaeghe, C., Nakagami, Y., Nguyenvu, L.T., Barczak, A.J.,
Killeen, N. and Erle, D.J. (2009) The protein disulﬁde isomerase AGR2 is
essential for production of intestinal mucus. Proc. Natl. Acad. Sci. U S A 106,
6950–6955.
[107] Zhao, F. et al. (2010) Disruption of Paneth and goblet cell homeostasis and
increased endoplasmic reticulum stress in Agr2/ mice. Dev. Biol. 338,
270–279.
[108] Hosoda, A., Tokuda, M., Akai, R., Kohno, K. and Iwawaki, T. (2010) Positive
contribution of ERdj5/JPDI to endoplasmic reticulum protein quality control
in the salivary gland. Biochem. J. 425, 117–125.
[109] Coe, H., Jung, J., Groenendyk, J., Prins, D. and Michalak, M. (2010) ERp57
modulates STAT3 signaling from the lumen of the endoplasmic reticulum. J.
Biol. Chem. 285, 6725–6738.[110] Chen, Y.C., Lu, Y.F., Li, I.C. and Hwang, S.P. (2012) Zebraﬁsh Agr2 is required
for terminal differentiation of intestinal goblet cells. PLoS One 7, e34408.
[111] Dumartin, L. et al. (2011) AGR2 is a novel surface antigen that promotes the
dissemination of pancreatic cancer cells through regulation of cathepsins B
and D. Cancer Res. 71, 7091–7102.
[112] Hoshijima, K., Metherall, J.E. and Grunwald, D.J. (2002) A protein disulﬁde
isomerase expressed in the embryonic midline is required for left/right
asymmetries. Genes Dev. 16, 2518–2529.
[113] Ni, M. and Lee, A.S. (2007) ER chaperones in mammalian development and
human diseases. FEBS Lett. 581, 3641–3651.
[114] Denzel, A., Molinari, M., Trigueros, C., Martin, J.E., Velmurgan, S., Brown, S.,
Stamp, G. and Owen, M.J. (2002) Early postnatal death and motor disorders in
mice congenitally deﬁcient in calnexin expression. Mol. Cell. Biol. 22, 7398–
7404.
[115] Wang, M. et al. (2010) Essential role of the unfolded protein response
regulator GRP78/BiP in protection from neuronal apoptosis. Cell Death Differ.
17, 488–498.
[116] Zhao, L., Longo-Guess, C., Harris, B.S., Lee, J.W. and Ackerman, S.L. (2005)
Protein accumulation and neurodegeneration in the woozy mutant mouse is
caused by disruption of SIL1, a cochaperone of BiP. Nat. Genet. 37, 974–
979.
[117] Green, D.R., Ferguson, T., Zitvogel, L. and Kroemer, G. (2009) Immunogenic
and tolerogenic cell death. Nat. Rev. Immunol. 9, 353–363.
[118] Lovat, P.E. et al. (2008) Increasing melanoma cell death using inhibitors of
protein disulﬁde isomerases to abrogate survival responses to endoplasmic
reticulum stress. Cancer Res. 68, 5363–5369.
[119] Goplen, D., Wang, J., Enger, P.O., Tysnes, B.B., Terzis, A.J., Laerum, O.D. and
Bjerkvig, R. (2006) Protein disulﬁde isomerase expression is related to the
invasive properties of malignant glioma. Cancer Res. 66, 9895–
9902.
[120] Toldo, S., Severino, A., Abbate, A. and Baldi, A. (2011) The role of PDI as
a survival factor in cardiomyocyte ischemia. Methods Enzymol. 489, 47–
65.
